# TactiSense IDE Trial of TactiCath SE for Paroxysmal Atrial Fibrillation

Study · id `cardio:ct-nct03354663` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03354663](<https://clinicaltrials.gov/study/NCT03354663>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03354663

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 156 participants.

## Technical summary

Registry record NCT03354663. Allocation not applicable; no masking; primary purpose treatment. Start 2017-12-11 (actual); primary completion 2018-08-02 (actual). Results posted on 2019-08-20.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 156 participants (enrolled count; ClinicalTrials.gov record NCT03354663, source copy `cardio:ctgov-nct03354663-2023-10-11`, retrieved 2026-10-26)
- Started: 2017-12-11 (actual) (ClinicalTrials.gov record NCT03354663, source copy `cardio:ctgov-nct03354663-2023-10-11`, retrieved 2026-10-26)
- Primary completion: 2018-08-02 (actual) (ClinicalTrials.gov record NCT03354663, source copy `cardio:ctgov-nct03354663-2023-10-11`, retrieved 2026-10-26)
- Completion: 2019-10-30 (actual) (ClinicalTrials.gov record NCT03354663, source copy `cardio:ctgov-nct03354663-2023-10-11`, retrieved 2026-10-26)
- Results first posted: 2019-08-20 (ClinicalTrials.gov record NCT03354663, source copy `cardio:ctgov-nct03354663-2023-10-11`, retrieved 2026-10-26)
- Countries: United States; Australia; Germany; Italy (ClinicalTrials.gov record NCT03354663, source copy `cardio:ctgov-nct03354663-2023-10-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03354663-2023-10-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: TactiSense IDE Trial of TactiCath SE for Paroxysmal Atrial Fibrillation
- Acronym: TactiSense
- Condition: Paroxysmal Atrial Fibrillation
- Intervention (Device): TactiCath SE
- Lead sponsor: Abbott Medical Devices
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Abbott (`cardio:abbott`)

## Provenance

Content hash: e30a990e101c916736d76c19bf52ef20122a8893d1df1dfe3ed137e3bee8d08d
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
